Thomas Schinecker has been appointed as lifecycle leader for sequencing and president of Roche's 454 Life Sciences, effective Aug. 1. He will replace 454's current president and CEO, Chris McLeod, who will retire in September.
Schinecker, who will report to Robert Yates, head of Roche Applied Science, is currently the general manager of Sweden for Roche Diagnostics. Previously, he held leadership positions in sales and marketing at Roche Diagnostics Austria. He holds a PhD in oncology from New York University.
Two Life Technologies executives have recently left the company. Kip Miller has left his position as president of the firm's genetic systems division in April. He is currently spending time with his family prior to planning his next steps. Previously, Miller led Invitrogen's biodiscovery division.
Kevin McKernan has also left Life Technologies. Most recently, he was vice president of advanced research R&D. Previously, he was the president of Agencourt Personal Genomics, which was acquired by Applied Biosystems in 2006.
Applied Biosystems and Invitrogen merged in 2008 to form Life Technologies.